Most previous patient-reported outcome results for CAR T-cell therapy have come from clinical trials testing these treatments, but information on how patients experience this treatment in real-world settings is scarce.

Dr Fabio Efficace and Dr Alice Di Rocco discuss their recent prospective study to measure real-world patient-reported symtomatic adverse events in those receiving CAR T-cell therapy for aggressive B-cell lymphomas, and how these outcomes match those reported by the physicans treating the patients. They discuss some of the rich and varied findings that they uncovered from their study.

Click here to read the full article:

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00128-6/fulltext

The Lancet Haematology in conversation with... is part of the Lancet Group podcast offering.

Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

Podcast editing: Matteo Simonetti

Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.

Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv